Stocky turns companies like CHUGAI PHARMACEUTICAL CO into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Cautious. 4519.T shows moderate growth momentum (65/100 Growth Compounder Score) but lacks the profitability depth to justify a stronger rating—Value Compounder Score of 56 reflects thin margins or inconsistent returns on capital. Leadership alignment at 52/100 suggests governance or incentive structures aren't yet investor-grade, raising questions about capital allocation discipline.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for CHUGAI PHARMACEUTICAL CO:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 58/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates CHUGAI PHARMACEUTICAL CO (4519.T) at 58/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. 4519.T shows moderate growth momentum (65/100 Growth Compounder Score) but lacks the profitability depth to justify a stronger rating—Value Compounder Score of 56 reflects thin margins or inconsistent returns on capital. Leadershi
4519.T's current Stocky Verdict is 58/100, placing it in the "Cautious" band. This composite combines a 65/100 Compounder score, 52/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for CHUGAI PHARMACEUTICAL CO yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
CHUGAI PHARMACEUTICAL CO scores 52/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Vulnerability Profile for CHUGAI PHARMACEUTICAL CO covers customer concentration, supply chain risk, refinancing walls, and regulatory exposure. Not yet finalised.
Sign up free and unlock the full analysis on 4519.T — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for 4519.T in the app.
